4-(4-Alkylpiperazin-1-yl)phenyl group: A novel class of basic side chains for selective estrogen receptor modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 24, 2003, Pages 4317-4320

  Watanabe, Nobuhide ^a   Nakagawa, Hiroshi ^a   Ikeno, Akihisa ^a   Minato, Hisao ^a   Kohayakawa, Chie ^a   Tsuji, Jun Ichi ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (1 PIPERIDINOETHOXY)PHENYL]SPIRO(INDENE 1,1' INDANE) 5,5' DIOL; ANTIESTROGEN; HYPOCHOLESTEROLEMIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYTOSOL; DOSE RESPONSE; DRUG BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0344064869     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.049     Document Type: Article

References (16)

1. (a) Jordan V.C. J. Med. Chem. 46:2003;883 (b) Jordan V.C. J. Med. Chem. 46:2003;1081 (c) Riggs B.L., Hartmann L.C. N. Engl. J. Med. 348:2003;618.
2. (a) Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. J. Natl. Cancer Inst. 90:1998;1371
3. (b) Plouffle L. Jr., Facog C.M. J. Soc. Gynecol. Invest. 7:2000;S38.
4. Rosati R.L., Jardine P.D.S., Cameron K.O., Thompson D.D., Ke H.Z., Toler S.M., Brown T.A., Pan L.C., Ebbinghaus C.F., Reinhold A.R., Elliot N.C., Newhouse B.N., Tjoa C.M., Sweetman P.M., Cole M.J., Arriola M.W., Gauthier J.W., Crawford D.T., Nickerson D.F., Pirie C.M., Qi H., Simmons H.A., Tkalcevic G.T. J. Med. Chem. 41:1998;2928.
5. Labrie F., Labrie C., Belanger A., Simard J., Giguere V., Tremblay G.J. Ster. Biochem. Mol. Biol. 79:2001;213.
6. Miller C.P., Harris H.A., Komm B.S. Drugs. 27:2002;117.
7. Lancet. 350:1997;1047.
8. Grese T.A., Sluka J.P., Bryant H.U., Cullinan G. J., Glasebrook A.L., Jones C.D., Matsumoto K., Palkowitz A.D., Sato M., Termine J.D., Winter M.A., Yang N.N., Dodge J.A. Proc. Natl. Acd. Sci. U.S.A. 94:1997;14105.
9. (a) Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engström O., Öhman L., Greene G.L., Gustafsson J.-A., Carlquist M. Nature. 389:1997;753 (b) Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. Cell. 95:1998;927.
10. For recent other examples, see: (a) Jørgensen A.S., Jacobsen P., Christiansen L.B., Bury P.S., Kanstrup A., Thorpe S.M., Bain S., Nærum L., Wassermann K. Bioorg. Med. Chem. Lett. 10:2000;399 (b) Kim Y.-W., Mobley J.A., Brueggemeier R.B. Bioorg. Med. Chem. Lett. 13:2003;1475, and references cited therein.
11. Watanabe N., Ikeno A., Minato H., Nakagawa H., Kohayakawa C., Tsuji J. J. Med. Chem. 46:2003;3961.
12. Kauffman R.F., Bensch W.R., Roudebush R.E., Cole H.W., Bean J.S., Phillips D.L., Monroe A., Cullinan G.J., Glasebrook A.L., Bryant H.U. J. Pharmacol. Exp. Ther. 280:1997;146. In addition, most of current SERMs have similar beneficial effects on lipid and bone metabolism. Therefore, the potency in cholesterol-lowering effect may correlate to that in preventive effect on osteoporosis; see: Levenson, A. S.; Kliakhandler, I. L.; Svoboda, K. M.; Pease, K. M.; Kaiser, S. A.; Ward, J. E., III; Jordan, V. C. Br. J. Cancer 2002, 87, 449.
13. (a) Grese T.M., Cho S., Finley D.R., Godfrey A.G., Jones C.D., Lugar C.H. III, Martin M.J., Matsumoto K., Pennington L.D., Winter M.A., Adrian M.D., Cole H.W., Magee D.E., Phillips D.L., Rowley E.R., Short L.L., Glasebrook A.L., Bryant H.U. J. Med. Chem. 40:1997;146 (b) Grese T.M., Pennington L.D., Sluka J.P., Adrian M.D., Cole H.W., Fuson T.R., Magee D.E., Phillips D.L., Rowley E.R., Shetler P.K., Short L.L., Venugopalan M., Yang N.N., Sato M., Glasebrook A.L., Bryant H.U. J. Med. Chem. 41:1998;1272.
14. (a) Levenson A.S., Jordan V.C. Cancer Res. 58:1998;1872
15. (b) Jordan V.C., Schafer J.M., Levenson A.S., Liu H., Pease K.M., Simons L.A., Zapf J.W. Cancer Res. 61:2001;6619
16. (c) Fahrnow M., Egner A., Curr U. Opin. Biotech. 10:1999;550.